Kornimate/medical-research-clean huggingface dataset:
vteval project - prospective cohort studies to evaluate and improve diagnostics, management strategies and risk stratification in vte

Conditions: Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE)

Summary: venous thromboembolism (vte) with its two clinical manifestations deep vein thrombosis (dvt) and pulmonary embolism (pe) is a life-threatening disease that is associated with considerable morbidity and mortality. the incidence of vte increases with age and it - as the third most common cardiovascular disease after ischemic heart disease and stroke - represents an important public health problem in industrialized countries with several aspects in need to be addressed. vteval project includes three long-term prospective observational studies to evaluate and improve vte diagnostics and management, treatment and outcome. the aims of the project include a systematic assessment of vte, i.e. disease status (symptoms, clinical and subclinical aspects) and risk profiles (classic, psychosocial and environmental factors), using a system-oriented approach. vteval collects three large prospective cohorts of patients with suspected and incident vte consisting of individuals with a clinical suspicion of acute pe, individuals with a clinical suspicion of acute dvt, and individuals with incidental diagnosis of vte). the standardized and harmonized data acquisition of the study establishes a sustainable resource for comprehensive research on vte, thus providing the basis for both short- and long-term analysis.


Eligibility criteria:
inclusion criteria: * age ≥18 years and informed written consent * clinical condition: * cohort 1: clinical suspicion of acute pe (with or without dvt) * cohort 2: clinical suspicion of acute dvt (without symptomatic pe) * cohort 3: incidentally diagnosed vte

Keywords: venous thromboembolism deep vein thrombosis pulmonary embolism cohort study/epidemiology outcome prognosis
acupuncture in infantile colic

Conditions: Infantile Colic

Summary: the purpose of this study is to investigate whether acupuncture influences: * the rate of infants who still fulfil the colic criterion after three intervention weeks * the time when the infants are crying, fussing or have intense bouts of colicky symptoms

infantile colic is a common problem. both the baby and the parents are suffering and there is a risk that the early relationship is disturbed. there is no known treatment that is both effective and harmless. acupuncture releases different neurotransmitters and hormones, gives pain reduction and affects digestion. acupuncture in infantile colic has not been studied in a scientific way even though the method is used in many countries. in this randomised study we will investigate if acupuncture affects symptoms in infantile colic.

Eligibility criteria:
inclusion criteria: * 2-8 weeks old otherwise healthy infants who are fussing/crying more than three hours/day, more than three days during one week exclusion criteria: * infants born before week 36 * infants who dont gain weight properly * infants taking other medicine than dimethicone or lactobacillus reuteri

Keywords: infantile colic
partner ii trial: placement of aortic transcatheter valves ii - nested registry 3/valve-in-valve

Conditions: Aortic Stenosis; Cardiomyopathy, Hypertrophic

Summary: to assess the safety and effectiveness of the sapien xt transcatheter heart valve in patients with a failing surgical aortic bioprosthetic valve.

a prospective, single-arm, multicenter clinical trial. the trial will enroll patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency. this is a partner ii nested registry.

Eligibility criteria:
inclusion criteria: 1. patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient \>40 mmhg or jet velocity greater than 4.0 m/s and an initial aortic valve area (ava) of ≤0.8 cm2 or indexed eoa \< 0.5 cm2/m2. qualifying echo must be within 60 days of the date of the procedure. 2. patient was symptomatic from his/her aortic valve stenosis, as demonstrated by nyha functional class ii or greater. 3. the heart team agreed (and verified in the case review process) that valve implantation would likely benefit the patient. 4. the study patient or the study patient's legal representative was informed of the nature of the study, agreed to its provisions and had provided written informed consent as approved by the institutional review board (irb) of the respective clinical site. 5. heart team consensus that the risk of surgical mortality or major morbidity ≥ 50%. 6. stenosed or insufficient surgically implanted bioprosthetic valve in the aortic position. exclusion criteria: 1. bioprosthetic valve labeled external diameter \< 21mm. 2. surgical or transcatheter valve in another position on the same side of the heart (mitral and tricuspid rings are not an exclusion). 3. infectious endocarditis within 6 months. 4. acute myocardial infarction ≤ 1 month (30 days) before the intended treatment.

Keywords: sapien xt partner ii cardiovascular disease heart disease aortic disease savr tavr failing surgical valve failing valve failing bioprosthetic valve
presence of ibd specific antibodies (asca, alca, acca, amca) in the sera of patients with spondyloarthropathy

Conditions: Psoriatic Arthritis; Ankylosing Spondylitis; Undifferentiated Spondyloarthropathy

Summary: a relationship between ibd and spondyloarthropathy is well recognized. asca ( anti saccharomyces cerevisiae antibodies)are considered to be a serological marker for crohn's disease and have been studied in patients with spondyloarthropathy with conflicting results. more recently, new serological markers for ibd have been described. these markers are antibodies to certain defined glycans , and their use may permit an improved diagnosis of ibd. the aim of our study is to investigate wether these new serological markers are present in the sera of patients with spondyloarthropathy.


Eligibility criteria:
inclusion criteria: * diagnosis of psoriatic arthritis, ankylosing spondylitis, or undifferentiated spondyloarthropathy exclusion criteria: * diagnosed inflammatory bowel disease

Keywords: spondyloarthropathy inflammatory bowel disease antibodies
medical students and psychoactive substances use

Conditions: Psychoactive Substances Consumption

Summary: medical students are heavy users of psychoactive substances, and even if levels of use vary depending on the universities, the average levels are higher than most other students. in france, however, the use of licit or illicit substance has not been precisely described in medical students. the aim of this study was therefore to define the different modes of consumption of medical students. methods: this study was a cross-sectional survey in medical students from the university of montpellier, and the investigators performed a cluster analysis of data. both medical students and residents were included. socio-demographic, medico-psychological and addictological data were collected.


Eligibility criteria:
inclusion criteria: * students had to be aged 18 * to be medical students exclusion criteria: - refusal

Keywords: medical student psychoactive substances alcohol tobacco at risk consumption
mecapegfilgrastim for the prevention of dalpiciclib -induced neutropenia in advanced breast cancer

Conditions: Metastatic Breast Cancer

Summary: neutropenia is a common complication from dalpiciclib. mecapegfilgramtim (code name hhpg-19k), a long-acting recombinant human granulocyte colony-stimulating factor (rhg-csf), has been developed. the study aim to evaluate the safety and efficiency of mecapegfilgrastim for prophylaxis of dalpiciclib -induced neutropenia in patients with advanced hr+/her2- breast cancer.


Eligibility criteria:
inclusion criteria: 1. age ≥18. 2. pathologically confirmed advanced hr+/her2- breast cancer: there is evidence of focal recurrence or metastasis, which is not suitable for surgical resection or radiotherapy for the purpose of cure. 3. no more than one line of chemotherapy is allowed for patients with recurrent and metastatic diseases. 4. eastern cooperative oncology group (ecog) performance status 0-2. 5. for patients with brain metastases, there is need for local treatment, and the brain lesions are stable for ≥ 3 months, and no need for dexamethasone or mannitol. 6. adequate organ function: (i) adequate hematologic function: hemoglobin ≥90 g/l, absolute neutrophil count (anc) ≥1.5×109/l, platelet count (plt) ≥100×109/l; (ii) adequate renal and hepatic function. 7. negative pregnancy test. exclusion criteria: 1. previous pathological diagnosis of her2 positive breast cancer. 2. previous treatment with cdk4/6 inhibitors. 3. major surgery, chemotherapy, radiotherapy, any research drug or other anti-cancer treatment within 2 weeks before entering the trial. 4. any other malignant tumor diagnosed within 3 years before entering the study, except non-melanoma skin cancer, basal cell or squamous cell skin cancer or cervical carcinoma in situ after radical treatment. 5. human immunodeficiency virus (hiv) infection or known acquired immunodeficiency syndrome (aids), active hepatitis b (hbv dna ≥ 1000 iu/ml), hepatitis c (hcv antibody positive and hcv-rna higher than the detection limit of the analytical method) or combined hepatitis b and hepatitis c co-infection. 6. within 6 months before entering the study, the following conditions occurred: myocardial infarction, severe / unstable angina pectoris, nyha grade 2 or above cardiac insufficiency, persistent arrhythmia ≥ grade 2 (according to nci-ctcae version 5.0), atrial fibrillation at any level, coronary / peripheral artery bypass grafting, symptomatic congestive heart failure, cerebrovascular accident (including transient ischemic attack or symptomatic pulmonary embolism). 7. inability to swallow, intestinal obstruction or other factors affecting drug administration and absorption.
the effect of acadesine on reducing cardiovascular and cerebrovascular adverse events in coronary artery bypass graft (cabg) surgery (study p05633 am1)(terminated)

Conditions: Coronary Artery Bypass; Myocardial Infarction; Ventricular Dysfunction, Left; Stroke; Cardiopulmonary Bypass

Summary: the purpose of this study is to determine whether acadesine is effective in reducing the cardiovascular and cerebrovascular adverse events in high-risk participants undergoing cabg surgery.


Eligibility criteria:
inclusion criteria: * a high risk participant undergoing non emergency cabg surgery requiring cpb and cardioplegia. * age: \>=50 years * at least one of the following risk factors: * female (but not pregnant or lactating), or * history of prior cabg, or * history of myocardial infarction (mi), or * history of ischemic stroke, or * left ventricular ejection fraction \<=30%, or * diabetes mellitus requiring insulin and/or antidiabetic agents. * significant coronary artery stenosis exclusion criteria: * planned valve replacement, carotid artery or aortic surgery, distal coronary endarterectomy,surgical ablation for cardiac arrhythmia, or ventricular aneurysmectomy, alone or with cabg surgery (repair for mild to moderate mitral valve disease with concomitant cabg is not excluded). * planned or staged major surgery within 30 days of cabg surgery * cabg surgery using intermittent aortic cross clamping without cardioplegia. * minimally invasive surgery (ie, without use of cpb). * mi within 5 days prior to surgery. * pre-operative or planned intra operative/postoperative use of intra-aortic balloon pump (iabp), ventricular assist device (vad), extra-corporeal membrane oxygenator (ecmo), or other mechanical hemodynamic assist device. * history or presence of gout or uric acid nephrolithiasis. * serum creatinine \>2 mg/dl (180 µmol/l). * serum alanine aminotransferase (alt) or aspartate aminotransferase (ast) \>2 x upper limit of normal (uln). * adenosine, aminophylline, nicotinic acid, pentoxifylline, theophylline, and any cardioplegia solution containing adenosine, dipyridamole or lidoflazine within 24 hours before surgery: * dipyridamole within 2 days and allopurinol or febuxostat within 4 days before surgery * food and drinks containing caffeine, theobromines or methylxanthines (such as coffee, tea, colas, some 'energy' drinks or chocolate) within 12 hours before surgery. * pregnancy
influence of an app on quality of life of women with endometriosis

Conditions: Endometriosis; Quality of Life

Summary: comparison of quality of life before and after 14 days of use of endo app® in endometriosis patients compared to non-users

introduction: endometriosis can significantly impair the quality of life of those affected. multimodal self-help measures are recommended but often difficult to access. smartphone apps have been shown to improve quality of life for other conditions with chronic pain. the aim of this study was to examine whether there is evidence of beneficial effects of the endo-app and whether a multicenter randomized controlled trial should be planned to substantiate these effects. methods: in a sample of n=106 women affected by endometriosis the present study determined the influence of the use of a smartphone app (endo-app ®) on their quality of life. among others, the validated questionnaire endometriosis health profile from oxford university was used for this purpose.

Eligibility criteria:
inclusion criteria: * suffering from endometriosis * 18 years or older * willing and capable of using a smartphone exclusion criteria: * minor under 18 years * endometriosis excluded * not capable of using a smartphone

Keywords: endometriosis quality of life smartphone application
factors determine the feasibility and surgical margin quality of sublobar resection for non-small cell lung cancer?

Conditions: Non-Small Cell Lung Cancer

Summary: sublobar resection (sr) has been recognized as non-inferior to lobectomy for small-sized non-small cell lung cancer (nsclc). this study aimed to systematically identify the potential factors influencing the feasibility and surgical margin quality of sr for small-sized nsclc. patients with small-sized nsclc (≤2 cm) who underwent sr or lobectomy between 2020 and 2023 were screened. surgical procedures were determined by discussion under the guidance of 3d-ctba. a surgical margin ≥ the maximum tumor diameter was considered sufficient. sr with a sufficient surgical margin was considered eligible. univariate and multivariate logistic regression analyses were performed to identify factors affecting the feasibility and margin quality of sr.

patients with small-sized pulmonary nodules who underwent lobectomy or sr between 2020 and 2023 in a single surgical team were retrospectively screened. all the surgical approach was jointly determined by three experienced surgeons (at least 15 years, doctor liang chen, weibing wu and zhicheng he). patients satisfied with the following criteria were initially reserved: (1) the maximum nodule diameter ≤ 2 cm; (2) single malignant nodule; (3) intentional resection; (4) histopathological confirmed primary nsclc. further, patients with (1) interlobar lesions; (2) nodules in the right middle lobe; (3) receiving neoadjuvant before surgery; (4) poor ct quality were excluded.

Eligibility criteria:
inclusion criteria: * the maximum nodule diameter ≤ 2 cm * single malignant nodule * intentional resection * histopathological confirmed primary non-small cell lung cancer exclusion criteria: * interlobar lesions * nodules located in the right middle lobe * receiving neoadjuvant before surgery * poor ct quality were excluded

Keywords: non-small cell lung cancer segmentectomy wedge resection margin quality
clinical utility of oxford cognitive screen test to screen cognitive impairment in post stroke patients

Conditions: Stroke

Summary: the goal of this type of study: clinical trial is to assess k-ocs clinical utility in participant population. the main aims: validate the reliability and validity of the korean version of the oxford cognitive screen (k-ocs) analyze its sensitivity, specificity, and diagnostic accuracy, and compare its examination participation rates with existing assessment tools to determine the effectiveness of k-ocs in detecting post-stroke cognitive impairment.


Eligibility criteria:
for stroke patients 1. inclusion criteria: * adults over 20 years of age * more than 72 hours elapsed since the onset of stroke symptoms. * after hearing a detailed explanation of this study and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to observe the precautions * involved individuals diagnosed with stroke by neurology and rehabilitation medicine specialists based on data acquired from 3t ge signa system (general electric, milwaukee, wi), brain magnetic resonance imaging (mri), and computed tomography (ct). 2. exclusion criteria: * who cannot meet the inclusion criteria for healthy voluteers 1. inclusion criteria: * over 20 years of age * a person who is performing an independent daily life * a person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing a detailed explanation of this study and fully understanding it 2. exclusion criteria: * who cannot meet the inclusion criteria
critically ill patients with covid-19 in hong kong: a multicentre observational cohort study

Conditions: COVID-19

Summary: the purpose of this case series is to describe the characteristics, organ dysfunction and support and 2 week outcomes of critically ill patients with ncov infection.

the 2019 novel-coronavirus (2019-ncov) is the cause of a cluster of unexplained pneumonia that started in hubei province in china 1. it has manifest into a global health crisis with escalating confirmed cases and spread across 15 countries. whilst it is currently an epidemic in china, the world health organization (who) global level risk assessment is set at high 2. sequencing showed that 2019-ncov is similar to bat severe acute syndrome (sars)-related coronaviruses found in chinese horseshoe bats 3. this is compatible with the initial epidemiological link with a local wet market which sells bats. furthermore, data sharing and sequencing data has facilitated development of accurate diagnostic tests. in contrast, our current understanding of the epidemiological and clinical features of 2019-ncov is limited. in a case series of 41 hospitalized patients with confirmed infection, at least 30% of these patients required critical care admission. these patients developed severe respiratory failure and 10% required mechanical ventilation and 5% needed extracorporeal membrane oxygenation support. more worryingly 2019-ncov infection was associated with 15% mortality. although these figures are likely overestimates due to unreported mild cases, there is currently no effective treatment. the optimal supportive care for patients with severe 2019-ncov infection is a research priority. the spread of the 2019-ncov epidemic to hong kong has started. patients have been admitted to the intensive care unit for multiorgan dysfunction. currently there are no published data focused specifically on critically ill patients with ncov infection. the purpose of this case series is to describe the characteristics, organ dysfunction and support and 2 week outcomes of critically ill patients with ncov infection.

Eligibility criteria:
inclusion criteria: * admission to icu * adult (≥18 years old) * confirmed case of 2019-ncov infection by 2019-ncov rna by reverse transcription polymerase chain reaction , isolation in cell culture of 2019-ncov from a clinical specimen or serum antibody to 2019-ncov exclusion criteria: - none
global physiotherapy in icu patients with high risk extubation failure

Conditions: Acute Respiratory Failure

Summary: this study aims to compare care provided by physiotherapists, combining respiratory care and early rehabilitation in intensive care unit, with standard care on the rate of acute respiratory failure within 7 days after extubation, in patients with high risk of extubation failure.

the extubation failure rate is 15% on average in intensive care units, but can reach 30% within 48 hours after extubation in high risk patients. their characteristics are : age \> 65 years, respiratory disease, body mass index \> 30 kg / m², intubation for more than 7 days, first extubation failure, and patient with ineffective cough associated with bronchial obstruction. the main reason for reintubation in these patients is acute respiratory failure with an ineffective cough, a bronchial obstruction, and neuromyopathy. on these three components, the physiotherapist can apply specific techniques. even though scientific literature recommends the presence of a physiotherapist before, during and after extubation in patients intubated for more than 48 hours, the benefits of physiotherapy in this context remains poorly explored. the main objective of this study is to compare the rate of acute respiratory failure within 7 days post-extubation in high-risk intensive care patients. the secondary objectives are to compare the rox index, the reintubation rate for acute respiratory failure within 7 days after extubation, the rate of pneumonia at 7 days, time spent on respiratory and mobilization care.

Eligibility criteria:
inclusion criteria: * patients with spontaneous ventilation weaning test. * consent form signed by the person support. exclusion criteria: * patients with a self-extubation, * patients with a tracheostomy, * patients with acute respiratory failure for acute lung edema (oap), * patients with decision to limit or stop active therapeutics (lata).

Keywords: physiotherapy intensive care unit extubation high-risk patients acute respiratory failure
using the conture® multi-lumen balloon to deliver accelerated partial breast brachytherapy

Conditions: Breast Cancer

Summary: this multiple site, prospective, non-randomized study has been designed to compile information on the efficacy of the contura™ mlb in delivering apbi in appropriately selected patients through evaluation of dosimetric success as compared with a single central lumen balloon device and through treatment outcomes.

data collected during this study will include baseline patient demographics, information related to the time of implant, radiation therapy details, and removal of the device as well as recurrence data, cosmetic outcomes and toxicities. the patient's follow-up data will be collected during the patient's standard follow-up visits.

Eligibility criteria:
inclusion criteria: * able and willing to sign informed consent * age 50 or older at diagnosis * life expectancy greater than 10 years (excluding diagnosis of breast cancer). * surgical treatment of the breast must have been lumpectomy. the margins of the resected specimen must be histologically free of tumor (negative surgical margins per nsabp criteria). * on histologic examination, the tumor must be dcis or invasive breast carcinoma. for patients with invasive breast cancer, an axillary staging procedure must be performed. either: 1. sentinel node biopsy (snb) alone if sentinel node(s) is/are negative; or 2. axillary dissection (minimum of six axillary nodes removed); and 3. the axillary node(s) must be pathologically negative. * the t stage must be tis, t1, or t2. if t2, the tumor must be ≤ 3.0 cm in maximum diameter. * estrogen receptor positive tumor exclusion criteria: * age \< 50 at diagnosis (regardless of histology) * pregnant or breast-feeding (if appropriate, patient must use birth control during the study) * active collagen-vascular disease * paget's disease of the breast * history of dcis or invasive breast cancer * prior breast or thoracic rt for any condition * multicentric carcinoma (dcis or invasive) * synchronous bilateral invasive or non-invasive breast cancer * surgical margins that cannot be microscopically assessed or that are positive or close * positive axillary node(s) * t stage of t2 with the tumor \> 3 cm in maximum diameter or a t stage \> 3 * estrogen receptor negative tumor

Keywords: breast cancer conture® brachytherapy